Literature DB >> 15176438

Detection of cannabinoid CB1, adenosine A1, muscarinic acetylcholine, and GABA(B) receptor-dependent G protein activity in transducin-deactivated membranes and autoradiography sections of rat retina.

Juha R Savinainen1, Jarmo T Laitinen.   

Abstract

1. Several G-protein-coupled receptors (GPCRs) have been localized to various layers of the vertebrate retina, using autoradiographic and immunohistochemical techniques, but the functional data concerning G protein activation are limited. Here, we establish optimized assay conditions to detect receptor-dependent G protein activity in membranes and tissue sections of the rat retina. 2. Agonist-stimulated [35S]GTPgammaS-binding responses were characterized for the Gi/o-linked adenosine A1, cannabinoid CB1, m2/m4 muscarinic acetylcholine, and GABA(B) receptors. Initial assumption was that G protein activity under "basal conditions" is high due to enrichment and activity of rhodopsin and transducin in this tissue. 3. We found that pretreatment of retina membranes with hydroxylamine (10 mM), a rhodopsin-inactivating drug, substantially (up to 60%) reduced basal G protein activity, thereby improving signal-to-noise ratio to detect agonist-stimulated G protein activation for all studied receptors. [35S]GTPgammaS autoradiography revealed that hydroxylamine specifically reduced basal binding in the transducin-enriched photoreceptor layer. In contrast, hydroxylamine did not affect GPCR signaling in brain membranes, indicating specific action on retinal transducin. 4. For all studied receptors, [35S]GTPgammaS autoradiography allowed localization of G protein activity to different retinal layers, with the bulk of signal detected in the ganglion cell layer. Strongest responses were observed for adenosine and muscarinic receptor agonists. Additional G protein activity was detected in the inner plexiform layer. 5. Responses to all tested agonists were reversed in the presence of appropriate receptor-selective antagonists, indicating receptor-mediated G protein activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176438     DOI: 10.1023/b:cemn.0000018619.18631.53

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  32 in total

1.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; J Millan; J M Derocq; P Casellas; C Congy; D Oustric; M Sarran; M Bouaboula; B Calandra; M Portier; D Shire; J C Brelière; G L Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

2.  Characterization of alpha 2-adrenoceptor subtypes in the porcine eye: identification of alpha 2A-adrenoceptors in the choroid, ciliary body and iris, and alpha 2A- and alpha 2C-adrenoceptors in the retina.

Authors:  A Wikberg-Matsson; J E Wikberg; S Uhlén
Journal:  Exp Eye Res       Date:  1996-07       Impact factor: 3.467

3.  Depalmitoylation of rhodopsin with hydroxylamine.

Authors:  D R Pepperberg; D F Morrison; P J O'Brien
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  Transducin activation by the bovine opsin apoprotein.

Authors:  A Surya; K W Foster; B E Knox
Journal:  J Biol Chem       Date:  1995-03-10       Impact factor: 5.157

5.  Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes.

Authors:  J R Savinainen; T Järvinen; K Laine; J T Laitinen
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

6.  Gamma-aminobutyrate type B receptor modulation of L-type calcium channel current at bipolar cell terminals in the retina of the tiger salamander.

Authors:  G Maguire; B Maple; P Lukasiewicz; F Werblin
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

7.  Endogenous adenosine and adenosine receptors localized to ganglion cells of the retina.

Authors:  K M Braas; M A Zarbin; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Presynaptic and postsynaptic localization of GABA(B) receptors in neurons of the rat retina.

Authors:  P Koulen; B Malitschek; R Kuhn; B Bettler; H Wässle; J H Brandstätter
Journal:  Eur J Neurosci       Date:  1998-04       Impact factor: 3.386

9.  Pharmacological characterization of muscarinic receptors mediating inhibition of adenylate cyclase activity in the rat retina.

Authors:  Z X Qu; R Fertel; N H Neff; M Hadjiconstantinou
Journal:  J Pharmacol Exp Ther       Date:  1988-09       Impact factor: 4.030

10.  Light microscopy of GTP-binding protein (Go) immunoreactivity within the retina of different vertebrates.

Authors:  T Terashima; T Katada; E Okada; M Ui; Y Inoue
Journal:  Brain Res       Date:  1987-12-15       Impact factor: 3.252

View more
  5 in total

1.  Global gene expression changes in rat retinal ganglion cells in experimental glaucoma.

Authors:  Dan Yi Wang; Arjun Ray; Kathryn Rodgers; Ceren Ergorul; Bradley T Hyman; Wei Huang; Cynthia L Grosskreutz
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-24       Impact factor: 4.799

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 3.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

Review 4.  Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.

Authors:  Despina Kokona; Panagiota-Christina Georgiou; Mihalis Kounenidakis; Foteini Kiagiadaki; Kyriaki Thermos
Journal:  Neural Plast       Date:  2016-01-06       Impact factor: 3.599

Review 5.  Expression and Function of the Endocannabinoid System in the Retina and the Visual Brain.

Authors:  Jean-François Bouchard; Christian Casanova; Bruno Cécyre; William John Redmond
Journal:  Neural Plast       Date:  2015-12-29       Impact factor: 3.599

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.